HOME >> BIOLOGY >> NEWS
Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies

ATLANTA -- Medroxyprogesterone acetate (MPA), a synthetic form of the naturally occurring steroid hormone progesterone widely used in contraceptives and hormone replacement therapy (HRT), increases aggression and anxiety and reduces sexual activity in female monkeys, according to a study published in the June edition of The Journal of Clinical Endocrinology and Metabolism. The investigators, from the Yerkes National Primate Research Center of Emory University and the Center for Behavioral Neuroscience (CBN) in Atlanta, say the findings may explain anecdotal reports of mood changes, depression and loss of libido in some women who use MPA for contraception and HRT.

In the counter balanced-designed study, Yerkes and CBN post-doctoral fellow Karen Pazol, PhD, compared aggression, anxiety and sexual behavior in six female pigtail macaques that received one week each of three different treatments: estrogen only, estrogen plus natural progesterone, and estrogen plus MPA.

Monkeys displayed significantly more aggressive and anxious behaviors when they received the estrogen/MPA combination as compared to when they received the estrogen only or the estrogen/progesterone combination. Dr. Pazol also noted a marked reduction in sexual activity during the estrogen/MPA treatment period.

"Our findings suggest MPA may be affecting certain neuroendocrine systems in a very different way than natural progesterone," explained Dr. Pazol. "In comparison to natural progesterone, MPA binds to glucocorticoid receptors with a much higher affinity and may have a greater impact on the brain's stress system."

Moreover, according to Dr. Pazol, unlike natural progesterone, MPA cannot be converted to the mood-regulating chemical, allopregnanolone. Changes in allopregnanolone levels have been associated with depression, anxiety disorders and premenstrual mood disorders in humans.

To identify MPA's behavioral e
'"/>

Contact: Kelly Thompson
kthomp8@emory.edu
404-727-9254
Emory University Health Sciences Center
7-Jun-2004


Page: 1 2

Related biology news :

1. Synthetic antifreeze could prevent ice growth
2. Synthetic clay could assist radioactive waste cleanup
3. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
4. Synthetic Lock Binds Some Molecules, Excludes Others
5. A Synthetic Peptide Destroys Brain Plaque Implicated in Alzheimers Disease
6. Cellular Engineers Design Custom Cell Surfaces Able To Adhere To Synthetic Materials
7. Synthetic Vitamin E And Natural Vitamin E Are Equally Powerful Antioxidents
8. Growth hormone and IBD: Reduction of intestinal inflammation, promotion of growth
9. Excess thyroid hormone harmful to fetus
10. Blood pressure hormone may inhibit growth of lung cancer
11. Hunt for a new plant hormone points to carotenoids

Post Your Comments:
(Date:7/25/2014)... a pleiotropic factor characterized by the existence of ... that confer to the protein deeply different characteristics. ... myelination occurring during development and the different phases ... degeneration, axon regrowth, remyelination and target reinnervation, Researchers ... that the soluble NRG1 upregulation observed in Schwann ...
(Date:7/25/2014)... of a molecular testing panel developed at UPMC ... initial surgery for patients with thyroid nodules and ... Cancer Institute (UPCI), partner with UPMC CancerCenter., The ... and other diagnostic testing agencies, improved the chances ... 30 percent, according to the study published this ...
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
Breaking Biology News(10 mins):Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
(Date:7/24/2014)... MENLO PARK, Calif. , July 24, 2014 ... biotechnology company in the emerging field of regenerative ... live webcast of a presentation to investors on ... 1:30 p.m. PDT.  The presentation will include an ... pipeline. To access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
(Date:7/24/2014)... 24, 2014 Research and Markets ... and Proteomics Analytical Instruments Market 2014-2018" report to ... Genomics is the study of the gene ... the structure and functions of proteomes or sets of ... technology. Genomics involves the mapping of genes and DNA ...
(Date:7/24/2014)... Three companies from the angelMD network were ... Competition. Out of 700 competition entrants, Chiron Health, Litesprite, ... round. In this round twenty teams are invited to ... mentoring from thought-leaders and medical entrepreneurs from all over ... commitment to the Livestrong vision around the Big C ...
Breaking Biology Technology:Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 23 angelMD Startups Make Livestrong Big C Semi-finals 2
Cached News: